Last reviewed · How we verify
DF289
DF289 is a small molecule that targets the [unknown molecular target] to [unknown therapeutic effect].
At a glance
| Generic name | DF289 |
|---|---|
| Also known as | Antibiotic |
| Sponsor | Salvat |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Further research is needed to understand the exact mechanism of action of DF289.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa (PHASE3)
- Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients (PHASE3)
- Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DF289 CI brief — competitive landscape report
- DF289 updates RSS · CI watch RSS
- Salvat portfolio CI